What is the most recent earnings date for ACRX stock?
ACELRX PHARMACEUTICALS INC (ACRX) last reported earnings on 11/8/2023.
NASDAQ:ACRX • US00444T2096
Past quarterly earnings results for ACELRX PHARMACEUTICALS INC (ACRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2023 | -0.08 | -0.29 | 71.99% | 91.49% | 120K | 134.13K | -10.53% | - |
| Q2 2023 | -0.40 | -0.54 | 26.01% | 66.67% | 250K | 76.5K | 226.80% | - |
| Q1 2023 | -0.75 | -1.42 | 47.10% | 37.50% | 612K | -100.00% | - | |
| Q4 2022 | -1.00 | -0.52 | -92.23% | 16.67% | 250K | 4.59M | -94.55% | - |
| Q3 2022 | -0.94 | -1.22 | 23.20% | 32.86% | 637.5K | -100.00% | -100.00% | |
| Q2 2022 | -1.20 | -1.53 | 21.57% | 25.00% | 561K | -100.00% | -100.00% | |
| Q1 2022 | -1.20 | -1.22 | 1.96% | 25.00% | 561K | -100.00% | -100.00% | |
| Q4 2021 | -1.20 | -1.43 | 15.97% | 40.00% | 1.887M | -100.00% | -100.00% | |
| Q3 2021 | -1.40 | -1.43 | 1.96% | 30.00% | 1.86M | 1.938M | -4.02% | 35.77% |
| Q2 2021 | -1.60 | -1.56 | -2.30% | - | 440K | 1.845M | -76.15% | -84.93% |
| Q1 2021 | -1.60 | -1.70 | 5.88% | 60.00% | 510K | 1.079M | -52.73% | 30.77% |
| Q4 2020 | -2.00 | -2.11 | 5.12% | - | 740K | 1.764M | -58.05% | - |
| Q3 2020 | -2.00 | -1.68 | -18.84% | - | 1.37M | 2.891M | -52.61% | - |
| Q2 2020 | -1.60 | -2.81 | 42.96% | - | 2.92M | 2.064M | 41.47% | - |
| Q1 2020 | -4.00 | -3.47 | -15.34% | - | 390K | 1.894M | -79.41% | - |
Notes
ACELRX PHARMACEUTICALS INC (ACRX) last reported earnings on 11/8/2023.
ACELRX PHARMACEUTICALS INC (ACRX) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, ACELRX PHARMACEUTICALS INC (ACRX) has beaten EPS estimates in 3 out of 4 releases.